MAZE Quote, Financials, Valuation and Earnings

LENZ Therapeutics, Inc. has a net margin of -- compared to Maze Therapeutics, Inc.'s net margin of -133.6%. Maze Therapeutics, Inc.'s return on equity of -35.16% beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.

Maze Therapeutics, Inc. has a consensus price target of $43.25, signalling upside risk potential of 1.53%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $53.50 which suggests that it could grow by 91.76%. Given that LENZ Therapeutics, Inc. has higher upside potential than Maze Therapeutics, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than Maze Therapeutics, Inc..

Maze Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Maze Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Maze Therapeutics, Inc. pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.

Maze Therapeutics, Inc. quarterly revenues are --, which are smaller than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. Maze Therapeutics, Inc.'s net income of -$30.1M is lower than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, Maze Therapeutics, Inc.'s price-to-earnings ratio is -- while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics, Inc. is 501.13x versus 44.50x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Liminatus Pharma has a net margin of -- compared to Maze Therapeutics, Inc.'s net margin of --. Maze Therapeutics, Inc.'s return on equity of -35.16% beat Liminatus Pharma's return on equity of --.

Maze Therapeutics, Inc. has a consensus price target of $43.25, signalling upside risk potential of 1.53%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Maze Therapeutics, Inc. has higher upside potential than Liminatus Pharma, analysts believe Maze Therapeutics, Inc. is more attractive than Liminatus Pharma.

Maze Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Maze Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics, Inc. pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.

Maze Therapeutics, Inc. quarterly revenues are --, which are larger than Liminatus Pharma quarterly revenues of --. Maze Therapeutics, Inc.'s net income of -$30.1M is higher than Liminatus Pharma's net income of --. Notably, Maze Therapeutics, Inc.'s price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics, Inc. is 501.13x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Oruka Therapeutics, Inc. has a net margin of -- compared to Maze Therapeutics, Inc.'s net margin of --. Maze Therapeutics, Inc.'s return on equity of -35.16% beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.

Maze Therapeutics, Inc. has a consensus price target of $43.25, signalling upside risk potential of 1.53%. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $46.90 which suggests that it could grow by 58.45%. Given that Oruka Therapeutics, Inc. has higher upside potential than Maze Therapeutics, Inc., analysts believe Oruka Therapeutics, Inc. is more attractive than Maze Therapeutics, Inc..

Maze Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.409, suggesting its less volatile than the S&P 500 by 140.861%.

Maze Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. Maze Therapeutics, Inc. pays -- of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.

Maze Therapeutics, Inc. quarterly revenues are --, which are smaller than Oruka Therapeutics, Inc. quarterly revenues of --. Maze Therapeutics, Inc.'s net income of -$30.1M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, Maze Therapeutics, Inc.'s price-to-earnings ratio is -- while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics, Inc. is 501.13x versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.